Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF)...
Saved in:
Main Author: | Jadwiga Nessler |
---|---|
Format: | article |
Language: | EN |
Published: |
Termedia Publishing House
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/7df11093d00449928650f3e7ff95d42c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
by: Avgerinos I, et al.
Published: (2019) -
Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
by: Olga Yuryevna Sukhareva, et al.
Published: (2016) -
Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker CM, et al.
Published: (2016) -
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
by: Steffen Pabel, et al.
Published: (2021) -
Left ventricular systolic dysfunction among nocturnal myocardial infarctions
by: A Ghaemian, et al.
Published: (2004)